02289 CHARMACY PHAR
- 13.880
- -0.020-0.14%
CHARMACY PHAR News
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
CHARMACY PHAR To Go Ex-Dividend On May 22nd, 2024 With 0.33082 HKD Dividend Per Share
April 27th - $CHARMACY PHAR(02289.HK)$ is trading ex-dividend on May 22nd, 2024. Shareholders of record on May 23rd, 2024 will receive 0.33082 HKD dividend per share on July 10th, 2024. The ex-div
創美藥業：2023年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Charmacy Pharmaceutical 2023 Profit Declines on Lower Asset Disposal Gains
Charmacy Pharmaceutical (HKG:2289) posted a 2023 net profit attributable to shareholders of 51.3 million yuan, or 0.4754 yuan per share, down from 90.5 million yuan, or 0.8377 yuan per share, a year e
Chuangmei Pharmaceutical (02289) will pay a final dividend of 0.3 yuan per share on July 10
Chuangmei Pharmaceutical (02289) announced that the company will pay a final dividend of 0 per share on July 10, 2024...
Chuangmei Pharmaceutical (02289) announced 2023 annual results, net profit of 51.34 million yuan, down 43.25% year on year
Chuangmei Pharmaceutical (02289) disclosed the 2023 annual results announcement. The group achieved operating income of 44.0 during the reporting period...
Chuangmei Pharmaceutical (02289) Elects Fourth Board of Directors
Chuangmei Pharmaceutical (02289) issued an announcement. The company reviewed and...
CHARMACY PHAR: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Charmacy Pharmaceutical's Profit to Drop by 45% in 2023
Charmacy Pharmaceutical (HKG:2289) expects a 45% year-over-year decline in attributable profit for the year 2023, the pharmaceutical products distributor said in a March 15 filing on the Hong Kong bou
Chuangmei Pharmaceutical (02289.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 15, 丨 Chuangmei Pharmaceutical (02289.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider recommending payment of a final dividend (if any).
Chuangmei Pharmaceutical (02289) Fa Ying Guang expects net profit to fall by about 45% year on year in 2023
Chuangmei Pharmaceutical (02289) issued an announcement. The Group expects the year ended December 31, 2023 (reporting period...
CHARMACY PHAR: NOTICE OF BOARD MEETING
CHARMACY PHAR: PROFIT WARNING
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Analysis
Price Target
No Data
